Minimally Invasive UroLift System Treatment Provides Rapid Symptom Relief and Improved Quality of Life, While Preserving Sexual Function*1,2
PLEASANTON, Calif. – February 20, 2019 – NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that 100,000 patients have been treated globally with its minimally invasive UroLift® System, a safe and effective treatment for men with Benign Prostatic Hyperplasia (BPH) that provides rapid symptom relief and improved quality of life while preserving sexual function.*1,2
BPH, also known as enlarged prostate, is a common condition marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep, and decreased quality of life.3 BPH affects over 40 million men in the United States alone.4 If left untreated, the condition can worsen over time and cause permanent bladder damage.5
“We are extremely proud to see the vast number of patients that have benefited from this minimally invasive technology, and we look forward to helping even more men achieve the same rapid, durable relief from BPH symptoms,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “Reaching this milestone is a significant achievement for not only the entire NeoTract team, but also for the physicians who are committed to using the UroLift System to provide exemplary care so that their patients can experience relief from the burdensome symptoms of BPH.”
“The vast majority of patients with BPH are under the impression that medication or invasive surgery are the only available options to treat their symptoms; however, more and more physicians are recommending the UroLift System treatment to their patients because it doesn’t carry the long-term side effects of other BPH treatments,” said Peter Walter**, M.D., F.A.C.S., of Western New York Urology Associates in Jamestown, NY. “After treating men using the UroLift System and observing the positive outcomes in their symptom relief and overall quality of life, I chose the UroLift System as my own treatment for my BPH symptoms.”
“The UroLift System has become an accepted standard of care treatment for men with enlarged prostate and the Prostatic Urethral Lift (PUL) is now recommended by the American Urologic Association BPH Treatment Guidelines,” said Steven Gange**, M.D., F.A.C.S., Summit Urology Group, Salt Lake City, Utah. “The symptoms associated with enlarged prostate can be extremely disruptive and burdensome, affecting the daily life of men with this condition. Fortunately, the UroLift System treatment allows men in diverse patient populations to experience significant improvements in BPH symptoms while preserving their sexual function*1,2, without requiring major surgery or the use of ongoing BPH medication. The ultimate result is these patients return to a better quality of life.”
*No instances of new, sustained erectile or ejaculatory dysfunction.
About the UroLift® System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function.*1,2 Patients also experienced significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System worldwide. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.
About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.
**Dr. Gange and Dr. Walter are paid consultants of NeoTract | Teleflex.
For Teleflex Incorporated:
Jake Elguicze, 610.948.2836
Treasurer and Vice President, Investor Relations
Nicole Osmer, 650.454.0504
*No instances of new, sustained erectile or ejaculatory dysfunction
1 Roehrborn J Urol 2013 LIFT Study
2 McVary, J Sex Med 2016
3 Speakman et al. 2014 BJUI International
4 NeoTract US Market Model estimates for 2018 based on IQVIA Health Drug and Procedure data
5 Tubaro et al. 2003 Drugs Aging
MAC00970-01 Rev A
Categorised in: Press Releases